News
Public · Published
Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026
Mirum Pharmaceuticals said data from its rare liver disease portfolio will be presented at AASLD's The Liver Meeting 2026, scheduled for November 5–9 in Denver. The program includes Phase 3 AZURE-1 results for brelovitug, Phase 2b VISTAS analyses for volixibat, and evidence on LIVMARLI in rare liver diseases.
Published:
Updated:
What happened
Mirum Pharmaceuticals said data from its rare liver disease portfolio will be presented at AASLD’s The Liver Meeting 2026, scheduled for November 5–9 in Denver. The program includes Phase 3 AZURE-1 results for brelovitug, Phase 2b VISTAS analyses for volixibat, and evidence on LIVMARLI in rare liver diseases.
Confirmed
Global impact / market context
The presentations could shape views of Mirum’s treatment prospects by adding clinical evidence on efficacy, safety, and patient outcomes across several rare liver conditions. Stronger evidence could support future use and revenue, while less favorable findings could weaken expectations; the article provides no results yet.
Analyst inference
This is a preview of data to be presented, not a report of the findings themselves. Investors therefore have no new outcome details here to assess. The range of studies spans late-stage and earlier research, so evidence strength and timing differ by treatment.
Analyst inference
What to watch
- At the meeting, review the full AZURE-1 Phase 3 results, including safety and efficacy findings for brelovitug and whether responses deepen with continued treatment. Confirmed
- Check the VISTAS analyses for results across itching severity, fatigue, and sleep, and whether the inflammatory bowel disease subgroup showed improvement without worsening disease activity. Confirmed
- Assess whether new LIVMARLI clinical and real-world evidence supports treatment outcomes in Alagille syndrome and PFIC; the supplied article gives no numerical findings. Analyst inference
Evidence
- Original source link unavailable